HALISTER: Allergan to Buy Tobira for $28.35/Share, $49.84/Share in CVR

Allergan to Buy Tobira for $28.35/Share, $49.84/Share in CVR

(Bloomberg) -- Allergan say Tobira Therapeutics deal will make give it a leading position in NASH.
  • Paying $28.35/share, in cash, and up to $49.84/share in Contingent Value Rights (CVRs)
  • Total potential consideration of up to $1.695b
Statement Link
Alert: HALISTER
Source: BFW (Bloomberg First Word)

Tickers
AGN US (Allergan plc)
TBRA US (Tobira Therapeutics Inc)

To de-activate this alert, click here

UUID: 7947283